13F Holdings
中文EN

MCRB Seres Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1609809 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY505.4%
TTM net income YoY-970.5%
TTM EPS YoY-1,766.7%
Revenue 3-yr CAGR-74.4%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-3,656.9%
Net margin-2,209.6%
FCF margin-3,010.4%
EBITDA margin-3,521.1%

Returns

ROE-144.3%
ROA-44.9%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets67.6%
Debt / equity0.00x
Current ratio1.65x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.36x
Accruals ratio16.2%
Payout ratio—
Capex / revenue1.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$789,000$0$0$7.13M$144.93M
R&D expense$49.06M$64.60M$117.60M$109.65M$141.89M
SG&A expense$39.16M$53.18M$77.50M$70.26M$69.26M
Operating income-$93.97M-$121.31M-$195.10M-$179.91M-$64.49M
Interest expense$0$0$2.47M$6.02M$2.91M
Income tax$0$0$0$0$0
Net income$5.70M$136,000-$113.72M-$250.16M-$65.58M
EBITDA-$89.84M-$115.85M-$188.85M-$173.28M-$58.55M
EPS (basic)0.640.00-17.77-2.31-0.72
EPS (diluted)0.640.00-17.77-2.31-0.72
Weighted avg. shares (diluted)8.87M7.77M6.40M108.08M91.70M
Balance sheet
Cash & equivalents$45.77M$39.46M$136.15M$171.22M$188.00M
Short-term investments——$0$18.31M$110.70M
Receivables$157,000$0———
Inventory——$29.65M$0—
Current assets$49.38M$38.67M$175.41M$194.76M$303.63M
PP&E, net$7.63M$11.53M$17.61M$22.98M$17.94M
Total assets$138.19M$139.81M$358.60M$348.78M$354.86M
Current liabilities$19.32M$41.22M$98.66M$85.60M$82.26M
Long-term debt——$110.00M$50.00M$24.05M
Total debt——$110.00M$50.00M$24.05M
Total liabilities$93.97M$126.03M$403.46M$338.00M$223.35M
Shareholders' equity$44.22M$13.78M-$44.86M$10.78M$131.51M
Net debt——-$26.15M-$121.22M-$163.95M
Shares outstanding9.56M8.65M135.04M125.22M91.89M
Cash flow statement
Operating cash flow$1.12M-$148.61M-$117.35M-$228.82M$6.69M
Capital expenditure$252,000$380,000$7.97M$9.82M$9.57M
Free cash flow$865,000-$148.99M-$125.33M-$238.64M-$2.88M
Investing cash flow-$42,000$142.29M$10.58M$82.43M$64.09M
Financing cash flow$13.90M-$90.37M$71.70M$129.60M$1.18M
Depreciation & amortization$4.13M$5.47M$6.24M$6.63M$5.95M
Stock-based compensation$10.84M$20.97M$34.10M$25.48M$20.22M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.